Vicore initiates human forearm blood flow study with C21
· Forearm blood flow is a technique to measure vasodilation and blood flow in man · If successful, this will allow a faster and more accurate development of new ATRAG molecules · Study approved by the Swedish Medical Products Agency and planned to start in Q2 2022Gothenburg, March 18, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing angiotensin II type 2 receptor agonists (ATRAGs), today announces initiating a clinical trial with C21* using a method for measuring human forearm blood flow in healthy volunteers. As part of the